The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension

Bibliography

• Egan BM, Zhao Y, Axon RN. Us trends in prevalence, awareness, treatment, and control of hypertension, 1988 – 2008. JAMA 2010;303(20):2043-50
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13
   PubMed Web of Science ®Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Bmj 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42(6):1206-52
   PubMed Web of Science ®Google Scholar
• Officers A; Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). JAMA 2002;288(23):2981-97
   PubMedGoogle Scholar
• Wald DS, Law M, Morris JK, Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122(3):290-300
   PubMed Web of Science ®Google Scholar
• Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010;12(11):869-78
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Reappraisal of european guidelines on hypertension management: a european society of hypertension task force document. J Hypertens 2009;27(11):2121-58
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN. Us trends in prevalence, awareness, treatment, and control of hypertension, 1988 – 2008. JAMA 2010;303(20):2043-50
   PubMed Web of Science ®Google Scholar
• Okonofua EC, Simpson KN, Jesri A, Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension 2006;47(3):345-51
   PubMed Web of Science ®Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23(11):2101-7
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Petrilla AA, Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165(10):1147-52
   PubMedGoogle Scholar
• Feldman RD, Zou GY, Vandervoort MK, A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53(4):646-53
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713-19
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jarugula V, Dieterich HA, Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47(8):515-31
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Valencia J, Kemp C, Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (hctz) and ramipril in healthy volunteers. Int J Clin Pract 2006;60(11):1343-56
   PubMedGoogle Scholar
• Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet 1992;22(1):22-31
   PubMed Web of Science ®Google Scholar
• Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 1984;54(Suppl 1):17-29
   PubMedGoogle Scholar
• Weir MR, Bush C, Anderson DR, Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1(4):264-77
   PubMed Web of Science ®Google Scholar
• Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs 2010;70(15):2011-49
   PubMed Web of Science ®Google Scholar
• Kostis JB, Cabrera J, Cheng JQ, Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA 2011;306(23):2588-93
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm (ascot-bpla): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906
   PubMed Web of Science ®Google Scholar
• Jamerson K, Weber MA, Bakris GL, Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417-28
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119(3):417-25
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Philipp T, Guerediaga J, Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27(7):1493-501
   PubMedGoogle Scholar
• Littlejohn TW III, Trenkwalder P, Hollanders G, Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009;25(4):951-9
   PubMed Web of Science ®Google Scholar
• Brown MJ, McInnes GT, Papst CC, Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (accelerate): a randomised, parallel-group trial. Lancet 2011;377(9762):312-20
   PubMed Web of Science ®Google Scholar
• Richter D, Mickel C, Acharya S, Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control. Int J Clin Pract 2011;65(5):613-23
   PubMedGoogle Scholar
• Axthelm C, Sieder C, Meister F, Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. Curr Med Res Opin 2012;28(1):69-78
   PubMed Web of Science ®Google Scholar
• Schweizer J, Ulmer HJ, Benduhn H, Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (+/- amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus hct 25 mg. Curr Med Res Opin 2011;27(1):131-40
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Weitzman R, Israel M, Efficacy and safety of aliskiren-based dual and triple combination therapies in us minority patients with stage 2 hypertension. J Am Soc Hypertens 2011;5(2):102-13
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Weitzman R, Purkayastha D, Aliskiren-based dual- and triple-combination therapies in high-risk us minority patients with stage 2 hypertension. J Am Soc Hypertens 2012;6(3):219-27
   PubMedGoogle Scholar
• Murray A, Koenig W, Garcia-Puig J, Long-term therapy with aliskiren/amlodipine/hydrochlorothiazide combination provides effective blood pressure reduction with good tolerability in patients with moderate to severe hypertension [poster 54]. J Clin Hypertens 2010;12(Suppl 1):A41
   Google Scholar
• Lacourciere Y, Taddei S, Konis G, Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J Hypertens 2012;30(10):2047-55
   PubMedGoogle Scholar
• Investigators O, Yusuf S, Teo KK, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, Aliskiren trial in type 2 diabetes using cardio-renal endpoints (altitude): rationale and study design. Nephrol Dial Transplant 2009;24(5):1663-71
   PubMed Web of Science ®Google Scholar